Circadian variations in proinflammatory cytokine concentrations in acute myocardial infarction;Ritmo luz/oscuridad de las citocinas proinflamatorias en el infarto agudo de miocardio

Revista Espanola de Cardiologia

Volumn 56, Issue 6, 2003, Pages 555-560

  Domínguez Rodríguez, Alberto ^a   Abreu González, Pedro ^b   García, Martín J ^a   de la Rosa, Alejandro ^a   Vargas, Manuel ^a   Marrero, Francisco ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Basic research; Circadian rhythm; Inflammation; Interleukins; Myocardial infarction

Indexed keywords

CYTOKINE; FIBRINOLYTIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; DARKNESS; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PATHOPHYSIOLOGY; SEX RATIO; STATISTICAL SIGNIFICANCE; SUNLIGHT; TISSUE INJURY;

EID: 0042810673     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13048152     Document Type: Article

References (23)

1. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
2. Ross R. The pathogenesis of atherosclerosis: a perspective from the 1990s. Nature 1993;362:801-9.
3. Miller MD, Krangel MS. Biology and biochemistry of the chemokines; a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992;12:17-46.
4. García-Moll X, Kaski JC. Cardiopatía isquémica: marcadores de inflamación y riesgo cardiovascular. Rev Esp Cardiol 1999;52: 990-1003.
5. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, et al. Circardian variation in the frequency of onset of acute myocardial infarction. The MILLIS Study Group. N Engl J Med 1985;313:1315-22.
6. Thompson DR, Blandford RL, Sutton TW, Marchant PR. Time of onset of chest pain in acute myocardial infarction. Int J Cardiol 1985;7:139-48.
7. Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514-8.
8. Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart AC, Aber VR, et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62:635-7.
9. Stene N, Panagiotis N, Tuck ML, Sowers JR, Mayes D, Berg G. Plasma norepinephrine levels are influenced by sodium intake, glucocorticoid administration, and circardian changes in normal man. J Clin Endocrinol Metab 1980;51:1340-5.
10. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation 1992;86(Suppl 3):95-9.
11. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99:2079-84.
12. Balbay Y, Tikiz H, Baptiste RJ, Ayaz S, Sasmaz H, Korkmaz S. Circulating interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction. Angiology 2001;52:109-14.
13. López-Sendón J, López de Sá E. Nuevos criterios de diagnóstico de infarto agudo de miocardio: orden en el caos. Rev Esp Cardiol 2001;54:669-74.
14. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
15. Le J, Vilcek J. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989;61:588-602.
16. Ikeda U, Ito T, Shimada K. Interleukin-6 and Acute Coronary Syndrome. Clin Cardiol 2001;24:701-4.
17. McCarthy MF. Interleukin-6 as central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes and visceral obesity: down-regulation with essential fatty acids, ethanol, and pentoxyfilline. Med Hipotheses 1999;52:465-77.
18. Sothern RB, Roitman-Johnson B, Kanabrocki EL, Yager JG, Roodel MM, Weatherbee JA, et al. Circadian characteristics of circulating IL-6 in men. J Allergy Clin Immunol 1995;95:1029-35.
19. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 2000; 101:1372-8.
20. Giri JG, Lomedico PT, Mizel SB. Studies on the synthesis and secretion of interleukin-1. I. A 33,000 molecular weight precursor for interleukin-1. J Immunol 1985;134:343-9.
21. Hernandes-Fernandes E, Coelho D, Missel-Correa JR, Kumpinski D. Alteraciones circadianas del sistema cardiovascular. Rev Esp Cardiol 2000;53:117-22.
22. Mehta JL, Saldeen TGP, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998;31:1217-25.
23. Pérez-Fernández R, Kaski JC. Interleucina-10 y enfermedad coronaria. Rev Esp Cardiol 2002;55:738-50.